How can biologically-based modeling of arsenic kinetics and dynamics inform the risk assessment process? - A workshop review

Toxicology and Applied Pharmacology

Volumn 232, Issue 3, 2008, Pages 359-368

  Kenyon, Elaina M ^a   Klimecki, Walter T ^b   El Masri, Hisham ^a   Conolly, Rory B ^c   Clewell, Harvey J ^d   Beck, Barbara D ^e  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^d Hamner Institute for Health Sciences   (United States)

^e GRADIENT   (United States)

Author keywords

Arsenic; Modeling; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ARSENIC;

CONFERENCE PAPER; GENETIC POLYMORPHISM; GENOMICS; HUMAN; MATHEMATICAL MODEL; NONHUMAN; PHARMACODYNAMICS; RISK ASSESSMENT;

ARSENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MATHEMATICS; METHYLATION; MODELS, BIOLOGICAL; NUTRITIONAL STATUS; RISK ASSESSMENT; SEX FACTORS; VARIATION (GENETICS);

EID: 53449101872     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.06.023     Document Type: Conference Paper

References (77)

1. Adonis M., Martinez V., Marin P., and Gil L. CYP1A1 and GSTM1 genetic polymorphisms in lung cancer populations exposed to arsenic in drinking water. Xenobiotica 35 (2005) 519-530
2. Ahsan H., Chen Y., Kibriya M.G., Slavkovich V., Parvez F., Jasmine F., Gamble M.V., and Graziano J.H. Arsenic metabolism, genetic susceptibility, and risk of premalignant skin lesions in Bangladesh. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 1270-1278
3. Alam M.G., Allinson G., Stagnitti F., Tanaka A., and Westbrooke M. Arsenic contamination in Bangladesh groundwater: a major environmental and social disaster. Int. J. Environ. Health Res. 12 (2002) 235-253
4. Aposhian H.V., and Aposhian M.M. Arsenic toxicology: five questions. Chem. Res. Toxicol. 19 (2006) 1-15
5. Aposhian H.V., Zakharyan R.A., Avram M.D., Sampayo-Reyes A., and Wollenberg M.L. A review of the enzymology of arsenic metabolism and a new potential role of hydrogen peroxide in the detoxication of the trivalent arsenic species. Toxicol. Appl. Pharmacol. 198 (2004) 327-335
6. Arnold L.L., Clark N.M., He J., Ohnishi T., and Cohen S.M. Effect of treatment with sodium arsenate (AsV) or sodium arsenite (AsIII) in the drinking water on the bladder urothelium of male and female F344 rats and C57BL/6 mice. In Society of Toxicology Annual Meeting (2007) Charlotte, NC
7. Benramdane L., Accominotti M., Fanton L., Malicier D., and Vallon J.J. Arsenic speciation in human organs following fatal arsenic trioxide poisoning-a case report. Clin. Chem. 45 (1999) 301-306
8. Buchet J.P., Lauwerys R., and Roels H. Comparison of the urinary excretion of arsenic metabolites after a single oral dose of sodium arsenite, monomethylarsonate, or dimethylarsinate in man. Int. Arch. Occup. Environ. Health 48 (1981) 71-79
9. Chen Y.C., Guo Y.L., Su H.J., Hsueh Y.M., Smith T.J., Ryan L.M., Lee M.S., Chao S.C., Lee J.Y., and Christiani D.C. Arsenic methylation and skin cancer risk in southwestern Taiwan. J. Occup. Environ. Med. 45 (2003) 241-248
10. Chen Y.C., Su H.J., Guo Y.L., Hsueh Y.M., Smith T.J., Ryan L.M., Lee M.S., and Christiani D.C. Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes Control 14 (2003) 303-310
11. Chen Y.C., Xu L., Guo Y.L., Su H.J., Smith T.J., Ryan L.M., Lee M.S., and Christiani D.C. Polymorphisms in GSTT1 and p53 and urinary transitional cell carcinoma in South-western Taiwan: a preliminary study. Biomarkers 9 (2004) 386-394
12. Chowdhury U.K., Rahman M.M., Sengupta M.K., Lodh D., Chanda C.R., Roy S., Quamruzzaman Q., Tokunaga H., Ando M., and Chakraborti D. Pattern of excretion of arsenic compounds [arsenite, arsenate, MMA(V), DMA(V)] in urine of children compared to adults from an arsenic exposed area in Bangladesh. J. Environ. Sci. Health Part A Tox. Hazard Subst. Environ. Eng. 38 (2003) 87-113
13. Clewell H.J., Thomas R.S., Gentry P.R., Crump K.S., Kenyon E.M., El-Masri H.A., and Yager J.W. Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report. Toxicol. Appl. Pharmacol. 222 (2007) 388-398
14. Cohen S.M., Arnold L.L., Eldan M., Lewis A.S., and Beck B.D. Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment. Crit. Rev. Toxicol. 36 (2006) 99-133
15. Cohen S.M., Arnold L.L., Uzvolgyi E., Cano M., St John M., Yamamoto S., Lu X., and Le X.C. Possible role of dimethylarsinous acid in dimethylarsinic acid-induced urothelial toxicity and regeneration in the rat. Chem. Res. Toxicol. 15 (2002) 1150-1157
16. Cohen S.M., Ohnishi T., Arnold L.L., and Le X.C. Arsenic-induced bladder cancer in an animal model. Toxicol. Appl. Pharmacol. 222 (2007) 258-263
17. Conolly R.B., Kimbell J.S., Janszen D., Schlosser P.M., Kalisak D., Preston J., and Miller F.J. Biologically motivated computational modeling of formaldehyde carcinogenicity in the F344 rat. Toxicol. Sci. 75 (2003) 432-447
18. Conolly R.B., Kimbell J.S., Janszen D.J., Schlosser P.M., Kalisak D., Preston J., and Miller F.J. Human respiratory tract cancer risks of inhaled formaldehyde: dose-response predictions derived from biologically-motivated computational modeling of a combined rodent and human dataset. Toxicol. Sci. 82 (2004) 279-296
19. Del Razo L.M., Styblo M., Cullen W.R., and Thomas D.J. Determination of trivalent methylated arsenicals in biological matrices. Toxicol Appl Pharmacol 174 (2001) 282-293
20. Deng F.R., Guo X.B., Chen L., Wang Z.Q., and Zhang K. [Relationship between 5,10-methylenetetrahydrofolate reductase genetic polymorphism and arsenic metabolism]. Beijing Da Xue Xue Bao 39 (2007) 149-152
21. Eblin K.E., Bowen M.E., Cromey D.W., Bredfeldt T.G., Mash E.A., Lau S.S., and Gandolfi A.J. Arsenite and monomethylarsonous acid generate oxidative stress response in human bladder cell culture. Toxicol. Appl. Pharmacol. 217 (2006) 7-14
22. El-Masri H.A., and Kenyon E.M. Development of a human physiologically based pharmacokinetic (PBPK) model for inorganic arsenic and its mono- and di-methylated metabolites. J. Pharmacokinet. Pharmacodyn. 35 (2008) 31-68
23. Gamble M.V., Liu X., Ahsan H., Pilsner J.R., Ilievski V., Slavkovich V., Parvez F., Chen Y., Levy D., Factor-Litvak P., and Graziano J.H. Folate and arsenic metabolism: a double-blind, placebo-controlled folic acid-supplementation trial in Bangladesh. Am. J. Clin. Nutr. 84 (2006) 1093-1101
24. Gamble M.V., Liu X., Ahsan H., Pilsner R., Ilievski V., Slavkovich V., Parvez F., Levy D., Factor-Litvak P., and Graziano J.H. Folate, homocysteine, and arsenic metabolism in arsenic-exposed individuals in Bangladesh. Environ. Health Perspect. 113 (2005) 1683-1688
25. Gentry P.R., Covington T.R., Mann S., Shipp A.M., Yager J.W., and Clewell III H.J. Physiologically based pharmacokinetic modeling of arsenic in the mouse. J. Toxicol. Environ. Health A 67 (2004) 43-71
26. Germolec D.R., Spalding J., Boorman G.A., Wilmer J.L., Yoshida T., Simeonova P.P., Bruccoleri A., Kayama F., Gaido K., Tennant R., Burleson F., Dong W., Lang R.W., and Luster M.I. Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors. Mutat. Res. 386 (1997) 209-218
27. Germolec D.R., Spalding J., Yu H.S., Chen G.S., Simeonova P.P., Humble M.C., Bruccoleri A., Boorman G.A., Foley J.F., Yoshida T., and Luster M.I. Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am. J. Pathol. 153 (1998) 1775-1785
28. Gilmour M.I., Jaakkola M.S., London S.J., Nel A.E., and Rogers C.A. How exposure to environmental tobacco smoke, outdoor air pollutants, and increased pollen burdens influences the incidence of asthma. Environ. Health Perspect. 114 (2006) 627-633
29. Gong Z., Lu X., Cullen W.R., and Le X.C. Unstable trivalent arsenic metabolites, monomethylarsonous acid and dimethylarsinous acid. J. Anal. Atom. Spectrom. 16 (2001) 1409-1413
30. Hansen H., Raab A., Jaspars M., Milne B., and Feldman J. Sulfur-containing arsenical mistaken for dimethylarsinous acid [DMA(III)] and identified as a natural metabolite in urine: major implications for studies on arsenic metabolism and toxicity. Chem. Res. Toxicol. 17 (2004) 1086-1091
31. Hayakawa T., Kobayashi Y., Cui X., and Hirano S. A new metabolic pathway of arsenite: arsenic-glutathione complexes are substrates for human arsenic methyltransferase Cyt19. Arch. Toxicol. 79 (2005) 183-191
32. Hsueh Y.M., Chiou H.Y., Huang Y.L., Wu W.L., Huang C.C., Yang M.H., Lue L.C., Chen G.S., and Chen C.J. Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol. Biomarkers Prev. 6 (1997) 589-596
33. Huang Y.K., Tseng C.H., Huang Y.L., Yang M.H., Chen C.J., and Hsueh Y.M. Arsenic methylation capability and hypertension risk in subjects living in arseniasis-hyperendemic areas in Southwestern Taiwan. Toxicol. Appl. Pharmacol. 218 (2007) 135-142
34. Hughes M.F., Del Razo L.M., and Kenyon E.M. Dose-dependent effects on tissue distribution and metabolism of dimethylarsinic acid in the mouse after intravenous administration. Toxicology 143 (2000) 155-166
35. Hughes M.F., and Kenyon E.M. Dose-dependent effects on the disposition of monomethylarsonic acid and dimethylarsinic acid in the mouse after intravenous administration. J. Toxicol. Environ. Health A 53 (1998) 95-112
36. Hughes M.F., Kenyon E.M., Edwards B.C., Mitchell C.T., Razo L.M., and Thomas D.J. Accumulation and metabolism of arsenic in mice after repeated oral administration of arsenate. Toxicol. Appl. Pharmacol. 191 (2003) 202-210
37. Khan M.M., Sakauchi F., Sonoda T., Washio M., and Mori M. Magnitude of arsenic toxicity in tube-well drinking water in Bangladesh and its adverse effects on human health including cancer: evidence from a review of the literature. Asian Pac. J. Cancer Prev. 4 (2003) 7-14
38. Klimecki W.T., Borchers A.H., Egbert R.E., Nagle R.B., Carter D.E., and Bowden G.T. Effects of acute and chronic arsenic exposure of human-derived keratinocytes in an in vitro human skin equivalent system: a novel model of human arsenicism. Toxicology In vitro 11 (1997) 89-98
39. Lee, E. (1999). A Physiologically Based Pharmacokinetic Model for the Ingestion of Arsenic in Humans. In Ph.D. Dissertation in Environmental Toxicology. University of California Irvine.
40. Li J., Waters S.B., Drobna Z., Devesa V., Styblo M., and Thomas D.J. Arsenic (+3 oxidation state) methyltransferase and the inorganic arsenic methylation phenotype. Toxicol. Appl. Pharmacol. 204 (2005) 164-169
41. Lindberg A.L., Ekstrom E.C., Nermell B., Rahman M., Lonnerdal B., Persson L.A., and Vahter M. Gender and age differences in the metabolism of inorganic arsenic in a highly exposed population in Bangladesh. Environ. Res. 106 (2008) 110-120
42. Lindberg A.L., Kumar R., Goessler W., Thirumaran R., Gurzau E., Koppova K., Rudnai P., Leonardi G., Fletcher T., and Vahter M. Metabolism of low-dose inorganic arsenic in a central European population: influence of sex and genetic polymorphisms. Environ. Health Perspect. 115 (2007) 1081-1086
43. Lu M., Wang H., Li X.F., Arnold L.L., Cohen S.M., and Le X.C. Binding of dimethylarsinous acid to cys-13alpha of rat hemoglobin is responsible for the retention of arsenic in rat blood. Chem. Res. Toxicol. 20 (2007) 27-37
44. Marafante E., Vahter M., Norin H., Envall J., Sandstrom M., Christakopoulos A., and Ryhage R. Biotransformation of dimethylarsinic acid in mouse, hamster and man. J. Appl. Toxicol. 7 (1987) 111-117
45. Marnell L.L., Garcia-Vargas G.G., Chowdhury U.K., Zakharyan R.A., Walsh B., Avram M.D., Kopplin M.J., Cebrian M.E., Silbergeld E.K., and Aposhian H.V. Polymorphisms in the human monomethylarsonic acid (MMA V) reductase/hGSTO1 gene and changes in urinary arsenic profiles. Chem. Res. Toxicol. 16 (2003) 1507-1513
46. McCarty K.M., Ryan L., Houseman E.A., Williams P.L., Miller D.P., Quamruzzaman Q., Rahman M., Mahiuddin G., Smith T., Gonzalez E., Su L., and Christiani D.C. A case-control study of GST polymorphisms and arsenic related skin lesions. Environ. Health 6 (2007) 5
47. Meza M.M., Yu L., Rodriguez Y.Y., Guild M., Thompson D., Gandolfi A.J., and Klimecki W.T. Developmentally restricted genetic determinants of human arsenic metabolism: association between urinary methylated arsenic and CYT19 polymorphisms in children. Environ. Health Perspect. 113 (2005) 775-781
48. Moore M.M., Harrington-Brock K., and Doerr C.L. Relative genotoxic potency of arsenic and its methylated metabolites. Mutat. Res. 386 (1997) 279-290
49. Preston R.J. Quantitation of molecular endpoints for the dose-response component of cancer risk assessment. Toxicol. Pathol. 30 (2002) 112-116
50. Pu Y.S., Yang S.M., Huang Y.K., Chung C.J., Huang S.K., Chiu A.W., Yang M.H., Chen C.J., and Hsueh Y.M. Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. Toxicol. Appl. Pharmacol. 218 (2007) 99-106
51. Rossman T.G. Mechanism of arsenic carcinogenesis: an integrated approach. Mutat. Res. 533 (2003) 37-65
52. Saady J.J., Blanke R.V., and Poklis A. Estimation of the body burden of arsenic in a child fatally poisoned by arsenite weedkiller. J. Anal. Toxicol. 13 (1989) 310-312
53. Schlawicke Engstrom K., Broberg K., Concha G., Nermell B., Warholm M., and Vahter M. Genetic polymorphisms influencing arsenic metabolism: evidence from Argentina. Environ. Health Perspect. 115 (2007) 599-605
54. Schoen A., Beck B., Sharma R., and Dube E. Arsenic toxicity at low doses: epidemiological and mode of action considerations. Toxicol. Appl. Pharmacol. 198 (2004) 253-267
55. Schwerdtle T., Walter I., and Hartwig A. Arsenite and its biomethylated metabolites interfere with the formation and repair of stable BPDE-induced DNA adducts in human cells and impair XPAzf and Fpg. DNA Repair (Amst) 2 (2003) 1449-1463
56. Snow E.T., Sykora P., Durham T.R., and Klein C.B. Arsenic, mode of action at biologically plausible low doses: what are the implications for low dose cancer risk?. Toxicol. Appl. Pharmacol. 207 (2005) 557-564
57. Steinmaus C., Moore L.E., Shipp M., Kalman D., Rey O.A., Biggs M.L., Hopenhayn C., Bates M.N., Zheng S., Wiencke J.K., and Smith A.H. Genetic polymorphisms in MTHFR 677 and 1298, GSTM1 and T1, and metabolism of arsenic. J. Toxicol. Environ. Health A 70 (2007) 159-170
58. Styblo M., Del Razo L.M., Vega L., Germolec D.R., LeCluyse E.L., Hamilton G.A., Reed W., Wang C., Cullen W.R., and Thomas D.J. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 74 (2000) 289-299
59. Subramaniam R.P., Crump K.S., Van Landingham C., White P., Chen C., and Schlosser P.M. Uncertainties in the CIIT model for formaldehyde-induced carcinogenicity in the rat: a limited sensitivity analysis - 1. Risk Anal. 27 (2007) 1237-1254
60. Tapio S., and Grosche B. Arsenic in the aetiology of cancer. Mutat Res 612 (2006) 215-246
61. Thomas D.J., Li J., Waters S.B., Xing W., Adair B.M., Drobna Z., Devesa V., and Styblo M. Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Exp. Biol. Med. (Maywood) 232 (2007) 3-13
62. Thomas D.J., Waters S.B., and Styblo M. Elucidating the pathway for arsenic methylation. Toxicol. Appl. Pharmacol. 198 (2004) 319-326
63. Tseng C.H. Arsenic methylation, urinary arsenic metabolites and human diseases: current perspective. J. Environ. Sci. Health, Part C 25 (2007) 1-22
64. Tseng C.H., Huang Y.K., Huang Y.L., Chung C.J., Yang M.H., Chen C.J., and Hsueh Y.M. Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Toxicol. Appl. Pharmacol. 206 (2005) 299-308
65. USEPA. National primary drinking water regulations; arsenic and clarification to compliance and new source contaminants monitoring: final rule. Federal Register 66 (2001) 6975-7066
66. USEPA. Guidelines for Carcinogen Risk Assessment EPA/630/P-03/001F, March 2005 (2005)
67. USEPA. Revised science issue paper: mode of carcinogenic action for cacodylic acid (dimethylarsinic acid, DMAV) and recommendations for dose response extrapolation. Health Effects Division, Office of Pesticide Programs (2006) 182
68. Vahter, M. (2002). Mechanisms of arsenic biotransformation. Toxicology 181-182, 211-217.
69. Vahter M., Concha G., Nermell B., Nilsson R., Dulout F., and Natarajan A.T. A unique metabolism of inorganic arsenic in native Andean women. Eur. J. Pharmacol. 293 (1995) 455-462
70. Valenzuela O.L., Borja-Aburto V.H., Garcia-Vargas G.G., Cruz-Gonzalez M.B., Garcia-Montalvo E.A., Calderon-Aranda E.S., and Del Razo L.M. Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic. Environ. Health Perspect 113 (2005) 250-254
71. Wei M., Wanibuchi H., Morimura K., Iwai S., Yoshida K., Endo G., Nakae D., and Fukushima S. Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis 23 (2002) 1387-1397
72. West J.D., and Marnett L.J. Alterations in gene expression induced by the lipid peroxidation product, 4-hydroxy-2-nonenal. Chem. Res. Toxicol. 18 (2005) 1642-1653
73. Wood T.C., Salavagionne O.E., Mukherjee B., Wang L., Klumpp A.F., Thomae B.A., Eckloff B.W., Schaid D.J., Wieben E.D., and Weinshilboum R.M. Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. J. Biol. Chem. 281 (2006) 7364-7373
74. Yoshida K., Chen H., Inoue Y., Wanibuchi H., Fukushima S., Kuroda K., and Endo G. The urinary excretion of arsenic metabolites after a single oral administration of dimethylarsinic acid to rats. Arch. Environ. Contam. Toxicol. 32 (1997) 416-421
75. Yoshida T., Yamauchi H., and Fan Sun G. Chronic health effects in people exposed to arsenic via the drinking water: dose-response relationships in review. Toxicol. Appl. Pharmacol. 198 (2004) 243-252
76. Yu L., Kalla K., Guthrie E., Vidrine A., and Klimecki W.T. Genetic variation in genes associated with arsenic metabolism: glutathione S-transferase omega 1-1 and purine nucleoside phosphorylase polymorphisms in European and indigenous Americans. Environ. Health Perspect. 111 (2003) 1421-1427
77. Yu R.C., Hsu K.H., Chen C.J., and Froines J.R. Arsenic methylation capacity and skin cancer. Cancer Epidemiol Biomarkers Prev. 9 (2000) 1259-1262